← Leaderboards
Yilun Sun
Case Western Reserve University
$633,871
Attributed
$1,267,741
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $513.3K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,267,741 · 1
By mechanism
U01$1,267,741 · 1
Top collaborators
- Daniel Eidelberg Spratt3 shared
Most similar at Case Western Reserve University
Same institution · by research overlap
- James Peter Basilion$13,402,848
- Baowei Fei$6,556,619
- John S Witte$28,734,737
- Stanton L Gerson$68,151,957
- Christopher C. Whalen$31,694,779
Others in their field
Other Emerging Leaders on “Ablation”
- James Jeffrey Sahn · 4e Therapeutics Inc.$7,064,669
- Kenneth B. Bader · University Of Chicago$6,109,156
- John R Lukens · University Of Virginia$5,842,869
- Juliette Elizabeth McGregor · University Of Rochester$5,567,728
- Jie Shen · Washington University$5,388,462
- Ashley E Webb · Brown University$5,147,077
Research focus
AblationAftercareAmericanAfrican AmericanAndrogen ReceptorBioinformaticsBiological MarkersBiomarker SignatureBiometryBiopsyBiopsy SpecimenBloodBlood CellsBone ImagingBurden Of IllnessCancer EtiologyCastrationCell Free DnaCessation Of LifeChemotherapyClinical CenterClinical ManagementClinical TrialsCollection
Grant awards (3)
Quantifying and Personalizing the Clinical Benefit of Metastasis-Directed Therapy in Men with De Novo Oligometastatic Prostate Cancer$309,210
U01 · FY2025 · CA
Quantifying and Personalizing the Clinical Benefit of Metastasis-Directed Therapy in Men with De Novo Oligometastatic Prostate Cancer$445,266
U01 · FY2024 · CA
Quantifying and Personalizing the Clinical Benefit of Metastasis-Directed Therapy in Men with De Novo Oligometastatic Prostate Cancer$513,265
U01 · FY2021 · CA